The United States osteoarthritis therapeutics market was valued at USD 3.43 Billion in 2025, driven by an increasing aging population and growing prevalence of osteoarthritis across the region. The market is anticipated to grow at a CAGR of 7.10% during the forecast period of 2026-2035, with the values likely to reach USD 6.81 Billion by 2035. The market is driven by advancements in biologics, the increasing use of non-pharmacological treatments, and the growing focus on personalized therapies, which is expected to fuel market growth during the forecast period.
Base Year
Historical Period
Forecast Period
In June 2023, Eupraxia Pharmaceuticals received U.S. FDA Fast Track designation for EP-104IAR, a long-acting corticosteroid therapy for knee osteoarthritis. Such approvals are expected to enhance market growth in the forecast period.
A major advancement in the United States osteoarthritis therapeutics market is an increase in the number of clinical trials. For instance, in July 2023, the Arthritis Foundation’s USD 20 million OA-CTN initiative launched the PIKASO trial to evaluate metformin’s potential in preventing post-traumatic osteoarthritis.
The market growth is also driven by key players heavily investing in R&D and collaborative clinical trials to develop disease-modifying treatments, reflecting a shift from symptom management to long-term therapeutic solutions.
Compound Annual Growth Rate
7.1%
Value in USD Billion
2026-2035
*this image is indicative*
Osteoarthritis therapeutics include a range of treatments such as analgesics, nonsteroidal anti-inflammatory drugs, corticosteroid injections, physical therapy, and surgical options. These aim to relieve joint pain, reduce inflammation, enhance mobility, and slow the progression of cartilage degradation. The market was valued at USD 3.43 Billion in 2025 and is expanding due to an aging population, increasing obesity, and growing awareness of early treatment. Continued advancements in drug development and patient care are expected to drive sustained growth.
Increasing Prevalence of Osteoarthritis to Accelerate the Market Growth
The substantial and rising prevalence of osteoarthritis (OA) in the United States continues to be a major driver of growth in the osteoarthritis therapeutics market. According to Michael Langworthy et al., 2024, osteoarthritis affects approximately 9,961 individuals per 100,000 in the United States, with the overall lifetime risk of developing symptomatic osteoarthritis ranging between 41% and 45%. This high and increasing disease burden is fostering sustained demand for advanced therapeutic options, thereby accelerating market expansion.
Some of the notable trends in the market are surge in FDA approvals and a growing focus on government initiatives:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Drug Class
Market Breakup by Dosage Form
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
NSAIDs Segment Based on Drug Class to Witness Substantial Growth
Based on drug class, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), other analgesics, corticosteroids, hyaluronic acid injections, and others. The NSAIDs segment is projected to dominate the market, attributed to the well-established efficacy of NSAIDs in reducing inflammation and relieving joint pain, and their widespread availability in both prescription and over-the-counter forms. Additionally, their relatively low cost and strong physician preference further contribute to their dominant market share.
The key features of the market report comprise clinical trials analysis, patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Bayer AG, established in 1863 and headquartered in Leverkusen, Germany, is a leading company in the market. Its product, Aleve (Naproxen Sodium), is a well-known pain reliever used in the treatment of osteoarthritis. Bayer has been involved in clinical studies, including trials for assessing treatment responsiveness to medications like naproxen for osteoarthritis stiffness. These initiatives highlight Bayer’s commitment to advancing osteoarthritis care and pain management solutions for patients in the United States.
Headquartered in New York City and established in 1849, Pfizer is a leading pharmaceutical company with a notable presence in the United States market. Pfizer has been involved in the clinical development of tanezumab, an investigational non-opioid monoclonal antibody targeting nerve growth factor (NGF). The Phase 3 trial results published in 2018 demonstrated significant improvements in pain relief and physical function for osteoarthritis patients, highlighting Pfizer’s commitment to addressing unmet needs in OA treatment through innovative biologic therapies.
Eli Lilly and Company is a global pharmaceutical leader actively involved in advancing osteoarthritis treatment in the United States. The company is committed to addressing chronic musculoskeletal conditions through innovative research and non-opioid therapeutic development. The company is actively developing LY3526318, a novel non-opioid drug targeting chronic osteoarthritis knee pain. Through continued innovation and focused therapeutic research, Lilly reinforces its strong commitment to addressing the growing burden of osteoarthritis.
Headquartered in Tampa, Florida, and established in 2007, Pacira BioSciences Inc. is a prominent American biopharmaceutical company specializing in non-opioid pain management. In March 2024, Pacira’s gene therapy candidate PCRX-201 received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for osteoarthritis of the knee, the first gene therapy to do so in this indication. Supported by positive Phase 1 data, PCRX-201 shows potential as a disease-modifying treatment. Alongside this innovation, Pacira continues to market Zilretta, an extended-release corticosteroid for osteoarthritis knee pain, reinforcing its leadership in the market.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Sanofi S.A., Bristol Myers Squibb, Assertio Holdings Inc., Anika Therapeutics Inc., and Bioventus LLC.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Dosage Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share